Search Results - "Doerr, Thomas"

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma by Matsue, Kosei, Iwasaki, Hiromi, Chou, Takaaki, Tobinai, Kensei, Sunami, Kazutaka, Ogawa, Yoshiaki, Kurihara, Mari, Midorikawa, Shuichi, Zaki, Mohamed, Doerr, Thomas, Iida, Shinsuke

“…This phase 1, open‐label, dose‐escalation study investigated the tolerated dose (recommended dose), safety, efficacy, and pharmacokinetics of pomalidomide…”
Get full text

The Collaborative Payer Provider Model Enhances Primary Care, Producing Triple Aim Plus One Outcomes: A Cohort Study by Doerr, Thomas, Olsen, Lisa, Zimmerman, Deborah

“…Rising health care costs are threatening the fiscal solvency of patients, employers, payers, and governments. The Collaborative Payer Provider Model (CPPM)…”
Get full text

Impact of an evidence-based computerized decision support system on primary care prescription costs by McMullin, S Troy, Lonergan, Thomas P, Rynearson, Charles S, Doerr, Thomas D, Veregge, Paul A, Scanlan, Edward S

“…Although newer, heavily promoted medications are commonly prescribed, published evidence and consensus guidelines often support the use of less expensive…”
Get full text

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial by Richardson, Paul G, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Lindsay, Jindriska, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Schey, Steve, Yu, Xin, Bensmaine, Amine, Zaki, Mohamed, Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Ben-Yehuda, Dina, Boccia, Ralph, Cavo, Michele, Chantry, Andrew, Chaudhry, Arvind, Corso, Alessandro, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Dürig, Jan, Engelhardt, Monika, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gisslinger, Heinz, Goldschmidt, Hartmut, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Huben, Marianne, Janakiram, Murali, Jenner, Matthew, João, Cristina, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Lauri, Birgitta, Leleu, Xavier, Matsue, Kosei, Mendeleeva, Larisa, Miller, Carole, Mohrbacher, Ann, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pavic, Michel, Pierola, Ana Alfonso, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Suzuki, Kenshi, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Wang, Xiang Sean, Yağci, Munci

“…As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an…”
Get full text

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6) by Sharman, Jeff P., Boccia, Ralph V., Doerr, Thomas, Conte, Kristin, Bai, Yang, Elliott, Brian, Andorsky, David J.

Get full text

IN AND OUT: THE CONVENIENCE OF SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA by Barnhizer, Tiffanie, Phillips, Tycel, Feldman, Tatyana, Doerr, Thomas, Sacchi, Mariana, Magarelli, Gabriella

“…Oncology Nursing Practice Clinical outcomes for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) remain poor and disease management is a…”
Get full text

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis by Davies, Kalatu R., Kamalakar, Rajesh, Yu, Junhua, Huang, Yinan, Wang, Anthony, Sail, Kavita, Doerr, Thomas, Sharmokh, Simon, Mutebi, Alex, Salles, Gilles

Get full text

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011) by Piasecki, Julia, Devries, Todd, Radhakrishnan, Aditya, Li, Yan, Heipel, Mark, Fox, Brian A., Beckett, Valeria, Cota Stirner, Mariana, Conte, Kristin, Doerr, Thomas, Mailankody, Sham, Wong, Sandy W., McCarthy, Philip L.

“…Background: Orva-cel, a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy, has shown promising preliminary efficacy and…”
Get full text

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011) by Mailankody, Sham, Jakubowiak, Andrzej J., Htut, Myo, Costa, Luciano J., Lee, Kelvin, Ganguly, Siddhartha, Kaufman, Jonathan L., Siegel, David Samuel DiCapua, Bensinger, William, Cota, Mariana, Doerr, Thomas, DeVries, Todd, Wong, Sandy Wai Kuan

“…Abstract only 8504 Background: Orva-cel is an investigational, BCMA-directed CAR T cell product with a fully human binder. Over 100 pts have been treated in…”
Get full text

MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM) by Richardson, Paul G., Bensmaine, Amine, Doerr, Thomas, Wang, Jianming, Zaki, Mohamed H.

“…Abstract only…”
Get full text

ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study by Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, Lugtenburg, Pieternella

Get full text

Poster: ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study by Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, Lugtenburg, Pieternella

Get full text

Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial by Richardson, Paul G., Rocafiguera, Albert Oriol, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darell, Facon, Thierry, San-Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Zaki, Mohamed H., Anderson, Kenneth Carl, Dimopoulos, Meletios A.

“…Abstract only…”
Get full text

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment by Matous, Jeffrey, Siegel, David S, Lonial, Sagar, Harvey, R. Donald, Kasserra, Claudia, Li, Yan, Chen, Min, Doerr, Thomas, Sternas, Lars, Zaki, Mohamed H., Jacques, Christian, Shah, Jatin J.

“…Background: Pomalidomide (POM) is indicated for patients (pts) with relapsed or refractory multiple myeloma (RRMM) who received ≥ 2 prior therapies including…”
Get full text

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan by Iida, Shinsuke, Iwasaki, Hiromi, Chou, Takaaki, Tobonai, Kensei, Sunami, Kazutaka, Ogawa, Yoshiaki, Kurihara, Mari, Midorikawa, Shuichi, Zaki, Mohamed H., Doerr, Thomas, Matsue, Kosei

“…Background: Patients (pts) with refractory or relapsed and refractory multiple myeloma (RRMM) who have exhausted treatment (Tx) with lenalidomide (LEN) or…”
Get full text

MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan by Hagiwara, Shotaro, Okamoto, Shinichiro, Matsue, Kosei, Iida, Shinsuke, Sunami, Kazutaka, Komeno, Takuya, Suzuki, Kenshi, Ando, Kiyoshi, Taniwaki, Masafumi, Tobinai, Kensei, Chou, Takaaki, Kaneko, Hitomi, Iwasaki, Hiromi, Uemura, Chie, Tamakoshi, Hiromi, Zaki, Mohamed H, Doerr, Thomas, Kuroda, Yoshiaki, Ichinohe, Tatsuo

“…Introduction: Pomalidomide plus low-dose dexamethasone (POM + LoDEX) is approved for the treatment of patients with relapsed and refractory multiple myeloma…”
Get full text

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment by Matous, Jeffrey, Siegel, David S., Duong, Hien K., Kasserra, Claudia, Chen, Min, Doerr, Thomas, Sternas, Lars, Zaki, Mohamed H., Jacques, Christian, Shah, Jatin J.

“…Pomalidomide (POM) is indicated for patients (pts) with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib,…”
Get full text

Modelling of the atomization of a plain liquid fuel jet in crossflow at gas turbine conditions by Rachner, Michael, Becker, Julian, Hassa, Christoph, Doerr, Thomas

“…The penetration and atomization of a plain jet of kerosene fuel in air crossflow were modelled and compared with the experiment at test conditions relevant to…”
Get full text

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial by Ichinohe, Tatsuo, Kuroda, Yoshiaki, Okamoto, Shinichiro, Matsue, Kosei, Iida, Shinsuke, Sunami, Kazutaka, Komeno, Takuya, Suzuki, Kenshi, Ando, Kiyoshi, Taniwaki, Masafumi, Tobinai, Kensei, Chou, Takaaki, Kaneko, Hitomi, Iwasaki, Hiromi, Uemura, Chie, Tamakoshi, Hiromi, Zaki, Mohamed H, Doerr, Thomas, Hagiwara, Shotaro

“…The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and…”
Get full text

Optimizing the AV Delay in DDD Pacemaker Patients with High Degree AV Block: Mitral Valve Doppler Versus Impedance Cardiography by KINDERMANN, MICHAEL, ERÖHLIG, GERD, DOERR, THOMAS, SCHIEFFER, HERMANN

“…In DDD‐pacemaker patients with high degree A V block, Doppler echocardiography of transmitral blood flow can be used to find the individually optimal AV delay…”
Get full text